Innate and early B cell responses to V. cholerae

对霍乱弧菌的先天和早期 B 细胞反应

基本信息

  • 批准号:
    9185932
  • 负责人:
  • 金额:
    $ 75.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-12-01 至 2018-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cholera remains an important cause of diarrheal illness, as evidenced by its recent emergence in post- earthquake Haiti. Scientific and policy leaders are increasingly calling for the use of preventive strategies such as vaccination for diarrheal diseases like cholera, but current cholera vaccines suffer from immunologic limitations. Most importantly, oral cholera vaccines elicit protection of short duration -- in contrast to naturl infection with V. cholerae, which induces long-lasting immunity. In the research proposed here, we seek to identify the earliest differences in the innate and B cell immune responses after natural infection versus cholera vaccination. We also aim to identify which of these early differences are most critical for the subsequent development of long term immunologic memory. Understanding these early differences may explain why only natural infection with V. cholerae gives rise to long term memory B cell responses which are important for protection against cholera. Because V. cholerae is a human-restricted pathogen, clinical studies are essential to address this question. We propose to draw upon existing collaborations between the Massachusetts General Hospital/Harvard Medical School (MGH/HMS), the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), the Emory Vaccine Center, and the Broad Institute of MIT/Harvard University to address this question in humans. Specifically, we will compare the activation of innate immune responses in mucosal tissue after cholera infection versus vaccination, and we will evaluate which of these differences correlate with long term memory B cell responses in cholera patients. We will also compare antibody secreting cell (ASC) responses in patients and vaccinees. Cloning of immunoglobulin genes and the production of these cloned antibodies from individual ASCs may improve our understanding of differences in the B cell responses between cholera patients and vaccine recipients, and the resulting antibodies may also provide tools with diagnostic and therapeutic potential. These studies will improve our understanding of the mechanisms through which innate immune responses at the mucosal surface foster long-lasting immunity and may point to novel strategies for improving upon current cholera vaccines.
说明(申请人提供):霍乱仍然是腹泻疾病的一个重要原因,最近在地震后海地出现的霍乱就是明证。科学和政策领导人越来越多地呼吁使用预防策略,如为霍乱等腹泻疾病接种疫苗,但目前的霍乱疫苗存在免疫学限制。最重要的是,口服霍乱疫苗产生的保护作用是短暂的--而自然感染霍乱弧菌则会诱导持久的免疫。在这里提出的研究中,我们试图确定自然感染和霍乱疫苗接种后先天和B细胞免疫反应的最早差异。我们的目标也是确定这些早期差异中的哪些对随后的长期免疫记忆的发展最关键。了解这些早期的差异可能解释为什么只有自然感染霍乱弧菌才能引起长期记忆B细胞反应,这对预防霍乱很重要。由于霍乱弧菌是一种人类限制的病原体,因此必须进行临床研究来解决这个问题。我们建议利用麻省总医院/哈佛医学院(MGH/HMS)、孟加拉国国际腹泻病研究中心(ICDDR,B)、埃默里疫苗中心和麻省理工学院/哈佛大学博德研究所之间的现有合作来解决这一人类问题。具体地说,我们将比较霍乱感染和疫苗接种后粘膜组织中天然免疫反应的激活情况,并评估其中哪些差异与霍乱患者的长期记忆B细胞反应相关。我们还将比较患者和疫苗接种者的抗体分泌细胞(ASC)反应。从单个ASCs中克隆免疫球蛋白基因并产生这些克隆抗体可能会提高我们对霍乱患者和疫苗接受者之间B细胞反应差异的了解,由此产生的抗体也可能提供具有诊断和治疗潜力的工具。这些研究将提高我们对粘膜表面的先天免疫反应促进持久免疫的机制的理解,并可能指出改进当前霍乱疫苗的新策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JASON B HARRIS其他文献

JASON B HARRIS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JASON B HARRIS', 18)}}的其他基金

Single dose azithromycin to prevent cholera in children
单剂量阿奇霉素预防儿童霍乱
  • 批准号:
    10632107
  • 财政年份:
    2021
  • 资助金额:
    $ 75.96万
  • 项目类别:
Single dose azithromycin to prevent cholera in children
单剂量阿奇霉素预防儿童霍乱
  • 批准号:
    10462780
  • 财政年份:
    2021
  • 资助金额:
    $ 75.96万
  • 项目类别:
Single dose azithromycin to prevent cholera in children
单剂量阿奇霉素预防儿童霍乱
  • 批准号:
    10297046
  • 财政年份:
    2021
  • 资助金额:
    $ 75.96万
  • 项目类别:
Innate and early B cell responses to V. cholerae
对霍乱弧菌的先天和早期 B 细胞反应
  • 批准号:
    8630383
  • 财政年份:
    2013
  • 资助金额:
    $ 75.96万
  • 项目类别:
Immune Responses to Vibrio cholerae infection and vaccination in Haiti
海地霍乱弧菌感染和疫苗接种的免疫反应
  • 批准号:
    8554355
  • 财政年份:
    2012
  • 资助金额:
    $ 75.96万
  • 项目类别:
Immune Responses to Vibrio cholerae infection and vaccination in Haiti
海地霍乱弧菌感染和疫苗接种的免疫反应
  • 批准号:
    8706677
  • 财政年份:
    2012
  • 资助金额:
    $ 75.96万
  • 项目类别:
Immune Responses to Vibrio cholerae infection and vaccination in Haiti
海地霍乱弧菌感染和疫苗接种的免疫反应
  • 批准号:
    8896410
  • 财政年份:
    2012
  • 资助金额:
    $ 75.96万
  • 项目类别:
Immune Responses to Vibrio cholerae infection and vaccination in Haiti
海地霍乱弧菌感染和疫苗接种的免疫反应
  • 批准号:
    8437751
  • 财政年份:
    2012
  • 资助金额:
    $ 75.96万
  • 项目类别:
Development of a small molecule screen for PhoP regulon inhibitors in Salmonella
沙门氏菌 PhoP 调节子抑制剂小分子筛选的开发
  • 批准号:
    7290659
  • 财政年份:
    2007
  • 资助金额:
    $ 75.96万
  • 项目类别:
Development of a small molecule screen for PhoP regulon inhibitors in Salmonella
沙门氏菌 PhoP 调节子抑制剂小分子筛选的开发
  • 批准号:
    7678707
  • 财政年份:
    2007
  • 资助金额:
    $ 75.96万
  • 项目类别:

相似海外基金

Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
  • 批准号:
    10549640
  • 财政年份:
    2023
  • 资助金额:
    $ 75.96万
  • 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
  • 批准号:
    2750554
  • 财政年份:
    2021
  • 资助金额:
    $ 75.96万
  • 项目类别:
    Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
  • 批准号:
    61319
  • 财政年份:
    2020
  • 资助金额:
    $ 75.96万
  • 项目类别:
    Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
  • 批准号:
    10013588
  • 财政年份:
    2020
  • 资助金额:
    $ 75.96万
  • 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
  • 批准号:
    20K07009
  • 财政年份:
    2020
  • 资助金额:
    $ 75.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
  • 批准号:
    10603473
  • 财政年份:
    2020
  • 资助金额:
    $ 75.96万
  • 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
  • 批准号:
    2342674
  • 财政年份:
    2020
  • 资助金额:
    $ 75.96万
  • 项目类别:
    Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
  • 批准号:
    10117194
  • 财政年份:
    2020
  • 资助金额:
    $ 75.96万
  • 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
  • 批准号:
    10115604
  • 财政年份:
    2020
  • 资助金额:
    $ 75.96万
  • 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
  • 批准号:
    10294224
  • 财政年份:
    2018
  • 资助金额:
    $ 75.96万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了